Intervention

QVA149

ClinicalTrials.gov intervention label

Clinical trials22
Recruiting0
Common conditions4
Lead sponsors shown1

Clinical trials

22 shown
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)NCT02634983 · 2016-06-03
COMPLETED
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDNCT02603393 · 2015-11-20
COMPLETED
Efficacy and Safety Study of QVA149 in COPD PatientsNCT02487446 · 2015-07-28
COMPLETED
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.NCT02487498 · 2015-07-27
COMPLETED
Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD PatientsNCT02442206 · 2015-05-18
COMPLETED
A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)NCT02233543 · 2014-11-30
COMPLETED
Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD PatientsNCT02125734 · 2014-04-01
COMPLETED
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.NCT01996319 · 2014-04-01
COMPLETED
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPDNCT01834885 · 2013-12-01
WITHDRAWN
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPDNCT01860066 · 2013-12-01
WITHDRAWN
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01
COMPLETED
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow LimitationNCT01712516 · 2012-12-01
COMPLETED
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.NCT01727141 · 2012-11-01
COMPLETED
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149NCT01709903 · 2012-11-01
COMPLETED
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow LimitationNCT01682863 · 2012-10-01
COMPLETED
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow LimitationNCT01610037 · 2012-10-01
COMPLETED
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01574651 · 2012-05-01
COMPLETED
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01529632 · 2012-05-01
COMPLETED
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01490125 · 2011-10-01
COMPLETED
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01285492 · 2011-01-01
COMPLETED
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsNCT01120691 · 2010-04-01
COMPLETED
A Study to Assess the Long-term Safety of QVA149NCT01120717 · 2010-04-01
COMPLETED

Trial status mix

COMPLETED20
WITHDRAWN2

Phase mix

PHASE317
PHASE45

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.